1. Home
  2. VYGR vs MG Comparison

VYGR vs MG Comparison

Compare VYGR & MG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • MG
  • Stock Information
  • Founded
  • VYGR 2013
  • MG 1978
  • Country
  • VYGR United States
  • MG United States
  • Employees
  • VYGR N/A
  • MG N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • MG Military/Government/Technical
  • Sector
  • VYGR Health Care
  • MG Consumer Discretionary
  • Exchange
  • VYGR Nasdaq
  • MG Nasdaq
  • Market Cap
  • VYGR 235.4M
  • MG 278.5M
  • IPO Year
  • VYGR 2015
  • MG 2009
  • Fundamental
  • Price
  • VYGR $4.22
  • MG $9.90
  • Analyst Decision
  • VYGR Strong Buy
  • MG Hold
  • Analyst Count
  • VYGR 9
  • MG 1
  • Target Price
  • VYGR $15.53
  • MG $11.00
  • AVG Volume (30 Days)
  • VYGR 374.5K
  • MG 81.6K
  • Earning Date
  • VYGR 03-03-2025
  • MG 03-05-2025
  • Dividend Yield
  • VYGR N/A
  • MG N/A
  • EPS Growth
  • VYGR N/A
  • MG N/A
  • EPS
  • VYGR 0.47
  • MG 0.36
  • Revenue
  • VYGR $163,784,000.00
  • MG $738,983,000.00
  • Revenue This Year
  • VYGR N/A
  • MG $6.49
  • Revenue Next Year
  • VYGR N/A
  • MG $2.75
  • P/E Ratio
  • VYGR $9.13
  • MG $28.36
  • Revenue Growth
  • VYGR 3.40
  • MG 6.85
  • 52 Week Low
  • VYGR $4.00
  • MG $7.45
  • 52 Week High
  • VYGR $10.66
  • MG $12.44
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 29.98
  • MG 51.54
  • Support Level
  • VYGR $4.20
  • MG $9.87
  • Resistance Level
  • VYGR $4.60
  • MG $10.13
  • Average True Range (ATR)
  • VYGR 0.31
  • MG 0.20
  • MACD
  • VYGR -0.08
  • MG -0.03
  • Stochastic Oscillator
  • VYGR 12.36
  • MG 41.41

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About MG Mistras Group Inc

MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.

Share on Social Networks: